Cite
HARVARD Citation
Weller, J. et al. (2019). Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet oncology. 20 (10), pp. 1444-1453. [Online].